트립토렐린 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the triptorelin market size is projected to be USD 1.83 billion in 2025, USD 1.91 billion in 2026, and reach USD 2.47 billion by 2031, growing at a CAGR of 5.25% from 2026 to 2031.

This report is Segmented by Drug Type (Pamoate, Acetate, Embonate), Route of Administration (IM, SC), Application (Prostate Cancer, Endometriosis, CPP, Uterine Fibroids, Radical Prostatectomy, Others), Distribution Channel (Hospital, Retail, Online Pharmacies, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Forecasts are Provided in Terms of Value (USD).

Global Triptorelin Market Trends and Insights

Rising Burden Of Prostate Cancer And Endometriosis

Global prostate cancer incidence reached 1.32 million cases in 2021, and the same body of disease burden work projects cases to reach 2.4 million by 2040, which keeps a large and growing treatment base in view for the triptorelin market. The United States alone is expected to record 333,830 new prostate cancer diagnoses and 36,320 deaths in 2026, and current treatment guidance continues to support LHRH agonists as first-line castration options in metastatic hormone-sensitive disease. Endometriosis adds a second major demand pool because the World Health Organization estimates that 190 million women of reproductive age are affected globally, and a 2026 review confirmed GnRH agonists as one of the strongest hormonal options for pain control across a long span of randomized evidence. The triptorelin market therefore, carries durable demand because both diseases have large active patient populations, and the endometriosis treatment pool still appears underpenetrated due to persistent diagnostic delay.

Growing Use In Central Precocious Puberty Management

A Phase 3 study published in October 2024 across 12 Chinese sites showed 100% luteinizing hormone suppression at month 6 after a single 22.5 mg triptorelin pamoate depot dose in children with central precocious puberty. The same study also reported pubertal regression or stabilization in 98.5% of participants and no grade 3 or higher adverse events, which gives the triptorelin market a strong pediatric efficacy and safety reference in a large future demand center. A second development came in April 2026 when population pharmacokinetics work for GenSci006 advanced the pediatric extrapolation framework for triptorelin acetate microspheres, which matters for new formulation approvals in the Asia-Pacific. These findings support a broader move from short-interval pediatric use toward longer-interval options, which can improve continuity during treatment courses that often last several years.

High Cost Of Peptide Synthesis And Sterile Injectable Manufacturing

Triptorelin is a decapeptide analog, and its production depends on expensive protected amino acids, high-grade purification, sterile fill finish capacity, and cold chain handling, which keeps costs elevated across the triptorelin market. These requirements create entry barriers for smaller players, but they also limit margin expansion for companies trying to compete with lower-priced generic or regional products in a technically demanding injectable category. Supply chain fragility is also visible because NHS Scotland issued a medicine supply alert in March 2025 for Gonapeptyl Depot 3.75 mg, with disruption continuing through January 2026. A supply issue in one sterile depot product can affect several therapeutic areas at once because the same molecule serves prostate cancer, endometriosis, and central precocious puberty. The triptorelin market, therefore faces a basic cost restraint that is not only about manufacturing expense, but also about maintaining a reliable supply across multiple clinical uses at the same time.

Other drivers and restraints analyzed in the detailed report include:

1. Shift Toward Long-Acting Depot Formulations
2. Expansion Of Fertility And Gender-Affirming Use Cases
3. Regulatory And Label Expansion Complexity Across Major Markets

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Triptorelin pamoate held 45.35% share in 2025, while triptorelin embonate is projected to grow at a 6.34% CAGR through 2031, which sets the current shape of competition across salt forms in the triptorelin market. Pamoate remains the largest format because it already has broad clinical familiarity and support across branded product lines used in prostate cancer, central precocious puberty, and other hormone suppression settings. That installed base matters because prescribers and procurement teams often stay with a depot format once it is established in hospital protocols. Embonate has gained fresh attention after the 2025 Swiss approval for subcutaneous Pamorelin LA and the completed European decentralized procedure for the 6 month Decapeptyl embonate formulation in advanced or metastatic prostate cancer.

Intramuscular administration accounted for 82.23% of revenue in 2025, which shows how firmly the triptorelin market still rests on established depot injection practice in oncology and endocrine care. The intramuscular route built this lead over many years because deeper depot delivery supports formulation volume and predictable release in an elderly prostate cancer population that is commonly treated in specialist settings. Subcutaneous delivery is the fastest-growing route, and the triptorelin market size for this route is projected to advance at 5.68% CAGR through 2031. Swiss approval for subcutaneous Pamorelin LA in 2025 gave this route a major institutional reference point because Debiopharm reported equivalent testosterone suppression with lower pain and reduced hematoma risk.

Complete Report Scope:

• By Drug Type
  • Triptorelin Pamoate
  • Triptorelin Acetate
  • Triptorelin Embonate
• By Route of Administration
  • Intramuscular (IM)
  • Subcutaneous (SC)
• By Application
  • Prostate Cancer
  • Radical Prostatectomy
  • Endometriosis
  • Central Precocious Puberty
  • Uterine Fibroids
  • Fertility Suppression and Assisted Reproduction Protocols
  • Others (Salivary Gland Cancer, Hormone-Sensitive Breast Cancer)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others (Specialty Pharmacies, Government Procurement Channels)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 40.36% of global revenue in 2025, which made it the largest regional contributor in the triptorelin market. The region stays ahead because the United States continues to carry a high prostate cancer burden, with 333,830 new diagnoses expected in 2026 under current guideline references. The triptorelin market in North America also benefits from established reimbursement structures and specialist oncology networks that can absorb long-acting depot therapy on a routine basis. The United States remains the main branded base through products such as Trelstar and Triptodur, while the mature prescribing environment also makes it one of the most active settings for generic substitution pressure. Europe remains a clinically important region because it houses entrenched branded depot use and a highly regulated approval and procurement environment.

Asia-Pacific is the fastest-growing geography, and the triptorelin market size in the region is projected to rise at 6.39% CAGR through 2031. China stands out because the 2024 Phase 3 central precocious puberty study supported 100% luteinizing hormone suppression with the 6-month pamoate formulation in Chinese children, which strengthens the case for broader pediatric use. Japan, India, Australia, and South Korea also contribute to the regional growth profile because specialist endocrine and oncology treatment capacity is expanding across several of the largest healthcare systems. The triptorelin market therefore has its strongest forward regional momentum in Asia-Pacific, where pediatric and oncology drivers are working together rather than independently.

1. Ache Laboratorios Farmaceuticos S.A.
2. Adium Pharma
3. Anhui Anke Bioengineering (Group) Co., Ltd.
4. Arbor Pharmaceuticals
5. Azurity Pharmaceuticals
6. Bachem Holding
7. Chengdu Tiantaishan Pharmaceutical Co., Ltd.
8. Debiopharm Group
9. Dr. Reddy's Laboratories
10. Ferring Pharmaceuticals
11. Ipsen
12. Knight Therapeutics Inc.
13. Orient Europharma Co., Ltd.
14. Sun Pharmaceuticals Industries
15. Tecnofarma S.A.
16. Teva Pharmaceutical Industries
17. Unilab Inc.
18. Verity Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Burden of Prostate Cancer and Endometriosis
  • 4.2.2 Growing Use in Central Precocious Puberty Management
  • 4.2.3 Shift Toward Long-Acting Depot Formulations
  • 4.2.4 Expansion of Fertility and Gender-Affirming Use Cases
  • 4.2.5 Emerging Clinical Trial Activity in New Indications
  • 4.2.6 Hospital Procurement Preference for High-Compliance Injectable Therapies
• 4.3 Market Restraints
  • 4.3.1 High Cost of Peptide Synthesis and Sterile Injectable Manufacturing
  • 4.3.2 Regulatory and Label Expansion Complexity Across Major Markets
  • 4.3.3 Formulation Switching Risk From Generic and Regional Competition
  • 4.3.4 Adherence Friction From Injection-Based Administration and Cold-Chain Handling
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Porter's Five Forces
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Suppliers
  • 4.6.3 Bargaining Power of Buyers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Drug Type
  • 5.1.1 Triptorelin Pamoate
  • 5.1.2 Triptorelin Acetate
  • 5.1.3 Triptorelin Embonate
• 5.2 By Route of Administration
  • 5.2.1 Intramuscular (IM)
  • 5.2.2 Subcutaneous (SC)
• 5.3 By Application
  • 5.3.1 Prostate Cancer
  • 5.3.2 Radical Prostatectomy
  • 5.3.3 Endometriosis
  • 5.3.4 Central Precocious Puberty
  • 5.3.5 Uterine Fibroids
  • 5.3.6 Fertility Suppression and Assisted Reproduction Protocols
  • 5.3.7 Others (Salivary Gland Cancer, Hormone-Sensitive Breast Cancer)
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies
  • 5.4.4 Others (Specialty Pharmacies, Government Procurement Channels)
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Ache Laboratorios Farmaceuticos S.A.
  • 6.3.2 Adium Pharma
  • 6.3.3 Anhui Anke Bioengineering (Group) Co., Ltd.
  • 6.3.4 Arbor Pharmaceuticals, LLC
  • 6.3.5 Azurity Pharmaceuticals
  • 6.3.6 Bachem Holding AG
  • 6.3.7 Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • 6.3.8 Debiopharm Group
  • 6.3.9 Dr. Reddy's Laboratories Ltd.
  • 6.3.10 Ferring Pharmaceuticals
  • 6.3.11 Ipsen S.A.
  • 6.3.12 Knight Therapeutics Inc.
  • 6.3.13 Orient Europharma Co., Ltd.
  • 6.3.14 Sun Pharmaceutical Industries Ltd.
  • 6.3.15 Tecnofarma S.A.
  • 6.3.16 Teva Pharmaceutical Industries Ltd.
  • 6.3.17 Unilab Inc.
  • 6.3.18 Verity Pharmaceuticals Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment